首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名:Clinical cancer research

缩写:CLIN CANCER RES

ISSN:1078-0432

e-ISSN:1557-3265

IF/分区:10.9/Q1

文章目录 更多期刊信息

共收录本刊相关文章索引11950条
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
Qianyu Zhang,Lin Lin,Wei Wang et al. Qianyu Zhang et al.
Purpose: This phase 1 clinical trial aims to evaluate the safety, expansion kinetics, and preliminary efficacy of non-armored, nanobody-derived GCC-targeted CAR-T cells in patients with heavily pretreated, metastatic colo...
Maria Vittoria Dieci,Elisa Gasparini,Lorenzo Nicolè et al. Maria Vittoria Dieci et al.
Purpose: We aimed to investigate the prognostic and predictive value of tumor infiltrating lymphocytes (TILs) for adjuvant immunotherapy in high-risk early TNBC. ...
Victor Malassigné,Julien Puech,Sandrine Imbeaud et al. Victor Malassigné et al.
Purpose: A subset of patients with human papillomavirus-positive oropharyngeal squamous cell carcinoma develops disease recurrence despite generally favorable outcomes. Reliable biomarkers for risk stratification remain l...
Luis H Cisneros,Merih D Toruner,Zafar Siddiqui et al. Luis H Cisneros et al.
Purpose: Pancreatic ductal adenocarcinoma (PDAC) frequently recurs after neoadjuvant therapy (NT) and curative-intent resection. Although major pathologic response predicts favorable outcomes, most patients achieve only m...
Laura Cipriani,Davide Mascolo,Stefano Scalera et al. Laura Cipriani et al.
Purpose: Clinical outcomes with immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC) range from durable disease control to rapid progression. Current biomarkers have limited ability to predict these d...
Amanda Heard,Rachel T Huynh,Christy R Hagan et al. Amanda Heard et al.
Cancer immunotherapy treatment has revolutionized cancer care. Of the many FDA approved immunotherapies, immune checkpoint inhibitors are the most widely prescribed, given their utility in treating both solid and hematopoietic diseases and ...
Alessandro Di Federico,Federica Pecci,Mark Jeng et al. Alessandro Di Federico et al.
Purpose: With rapidly expanding treatment options for patients with EGFR-mutated non-small cell lung cancer (NSCLC), identifying biomarkers that may assist treatment selection is critical. The impact of EGFR amplification...
Lucjan Wyrwicz,Arunee Dechaphunkul,Jong-Seok Lee et al. Lucjan Wyrwicz et al.
Purpose: The bispecific antibodies lomvastomig and tobemstomig block the immune checkpoint receptor PD-1 and either TIM-3 or LAG-3, respectively. This phase 2 study assessed their efficacy compared with nivolumab in CPI-n...
Federica Rubbino,Luana Greco,Alessandro Scagliotti et al. Federica Rubbino et al.
Purpose: Controversy exists regarding the association between HFE H63D polymorphism and pancreatic ductal adenocarcinoma (PDAC). This study initially assessed the frequency of H63D in PDAC patients and subsequently invest...